Haemodynamic and clinical effects of ularitide in decompensated heart failure

European Heart Journal

Volumn 27, Issue 23, 2006, Pages 2823-2832

  Mitrovic, Veselin ^a   Seferovic, Petar M ^b   Simeunovic, Dejan ^b   Ristic, Arsen D ^b   Miric, Milutin ^c   Moiseyev, Valentin S ^d   Kobalava, Zhanna ^d   Nitsche, Klaus ^e   Forssmann, Wolf Georg ^f   Lüss, Hartmut ^g   Meyer, Markus ^g  

^a KERCKHOFF HEART CENTER   (Germany)

^b University Clinical Center of Serbia   (Serbia)

^c ZVEZDARA UNIVERSITY MEDICAL CENTER   (Serbia)

^d PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^e Hospital St Vincenz   (Serbia)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g IPF PHARMACEUTICALS GMBH   (Germany)

Author keywords

Congestive heart failure; Decompensated heart failure; Natriuretic peptide; Randomized clinical trial; Ularitide; Urodilatin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; NITRIC ACID DERIVATIVE; PLACEBO; SPIRONOLACTONE; URODILATIN; WARFARIN;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIURETIC ACTIVITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HEART RATE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; KIDNEY FUNCTION; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SWEATING; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT OUTCOME; VASODILATATION;

EID: 33845342902     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl337     Document Type: Article

References (35)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-e151.
2. Abassi ZA, Powell JR, Golomb E, Keiser HR. Renal and systemic effects of urodilatin in rats with high-output heart failure. Am J Physiol 1992;262:F615-F621.
3. Forssmann WG, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res 2001;51:450-462.
4. de Zeeuw D, Janssen WM, de Jong PE. Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int 1992;41:1115-1133.
5. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, Kambayashi Y, Inouye K, Imura H. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-1412.
6. Atlas SA, Maack T. Effects of atrial natriuretic factor on the kidney and the renin-angiotensin-aldosterone system. Endocrinol Metab Clin North Am 1987;16:107-143.
7. van der ZK, Houben AJ, Hofstra L, Kroon AA, de Leeuw PW. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am J Physiol Heart Circ Physiol 2003;285:H1206-H1212.
8. Meyer M, Richter R, Brunkhorst R, Wrenger E, Schulz-Knappe P, Kist A, Mentz P, Brabant EG, Koch KM, Rechkemmer G, Forssmann WG. Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects. Am J Physiol 1996;271:F489-F497.
9. Carstens J, Jensen KT, Pedersen EB. Metabolism and action of urodilatin infusion in healthy volunteers. Clin Pharmacol Ther 1998;64:73-86.
10. Hildebrandt DA, Mizelle HL, Brands MW, Hall JE. Comparison of renal actions of urodilatin and atrial natriuretic peptide. Am J Physiol 1992;262:R395-R399.
11. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998;274:F63-F72.
12. Bestle MH, Olsen NV, Christensen P, Jensen BV, Bie P. Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. Am J Physiol 1999;276:R684-R695.
13. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-1491.
14. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-1905.
15. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng ML, Elkayam U. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-1108.
16. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-393.
17. Elsner D, Muders F, Muntze A, Kromer EP, Forssmann WG, Riegger GA. Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure. Am Heart J 1995;129:766-773.
18. Kentsch M, Ludwig D, Drummer C, Gerzer R, Muller-Esch G. Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur J Clin Invest 1992;22:662-669.
19. Mitrovic V, Luss H, Nitsche K, Forssmann K, Maronde E, Fricke K, Forssmann WG, Meyer M. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005;150:1239.
20. Rooke GA, Feigl EO. Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circ Res 1982;50:273-286.
21. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-1540.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
23. Lamb EJ, Wood J, Stowe HJ, O'Riordan SE, Webb MC, Dalton RN. Susceptibility of glomerular filtration rate estimations to variations in creatinine methodology: a study in older patients. Ann Clin Biochem 2005;42:11-18.
24. Uleman JS. A nonparametric comparison of two small sampels with many ties. Psych Bull 1968;70:794-797.
25. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-253.
26. Northridge DB, McMurray J, Dargie HJ. Atrial natriuretic factor in chronic heart failure. Herz 1991;16:92-101.
27. Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbard EB. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;78:896-901.
28. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003;4:72-80.
29. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710-1718.
30. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-141.
31. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 1993;87:70-75.
32. Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M, Willnow T, Bruemmer D, Graf K, Dietz R, Willenbrock R. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci 2002;71:2701-2712.
33. Hebeler RF Jr, Mehmet C. Effect of perioperative nesiritide administration on postoperative renal function and clinical outcomes in patiens untergoing cardiothoracic surgery. Abstracts from the 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. Circulation 2006;113:e807-e808. P104.
34. Increased mortality greater use of hospital resources observed in heart failure patients who chronically receive diuretics. http://www.adhereregistry. com/press/ADHERE_Diuretics_in_HF_patients_withRI.pdf.Adhere 2004.
35. Kentsch M, Drummer C, Gerzer R, Muller-Esch G. Severe hypotension and bradycardia after continuous intravenous infusion of urodilatin (ANP 95-126) in a patient with congestive heart failure. Eur J ClinInvest 1995;25:281-283.